Literature DB >> 14668711

Revised U.S. surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases--United States and worldwide, December 2003.

.   

Abstract

During the 2003 epidemic of severe acute respiratory syndrome (SARS), CDC and the Council of State and Territorial Epidemiologists (CSTE) developed surveillance criteria to identify persons with SARS. The surveillance case definition changed throughout the epidemic as understanding of the clinical, laboratory, and transmission characteristics of SARS-associated coronavirus (SARS-CoV) increased. On June 26, CSTE adopted a position statement to add SARS-CoV disease to the National Notifiable Disease Surveillance System (NNDSS). The position statement included criteria for defining a SARS case for national reporting. On November 3, CSTE issued a new interim position statement with a revised SARS case definition. This report summarizes the new U.S. surveillance case definition for SARS and updates reported cases of SARS worldwide and in the United States.

Entities:  

Mesh:

Year:  2003        PMID: 14668711

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  40 in total

1.  Mad cow and other maladies: update on emerging infectious diseases.

Authors:  Cristie Columbus
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

Review 2.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

4.  The 7a accessory protein of severe acute respiratory syndrome coronavirus acts as an RNA silencing suppressor.

Authors:  Sumona Karjee; Ankita Minhas; Vikas Sood; Sanket S Ponia; Akhil C Banerjea; Vincent T K Chow; Sunil K Mukherjee; Sunil K Lal
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

5.  The ORF7b protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is expressed in virus-infected cells and incorporated into SARS-CoV particles.

Authors:  Scott R Schaecher; Jason M Mackenzie; Andrew Pekosz
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Severe acute respiratory syndrome coronavirus gene 7 products contribute to virus-induced apoptosis.

Authors:  Scott R Schaecher; Erin Touchette; Jill Schriewer; R Mark Buller; Andrew Pekosz
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

7.  Pulmonary tuberculosis and SARS, China.

Authors:  Wei Liu; Arnaud Fontanet; Pan-He Zhang; Lin Zhan; Zhong-Tao Xin; Fang Tang; Laurence Baril; Wu-Chun Cao
Journal:  Emerg Infect Dis       Date:  2006-04       Impact factor: 6.883

8.  SARS antibody test for serosurveillance.

Authors:  Po-Ren Hsueh; Chuan-Liang Kao; Chun-Nan Lee; Li-Kuan Chen; Mei-Shang Ho; Charles Sia; Xin De Fang; Shugene Lynn; Tseng Yyuan Chang; Shi Kau Liu; Alan M Walfield; Chang Yi Wang
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883

9.  An immunosuppressed Syrian golden hamster model for SARS-CoV infection.

Authors:  Scott R Schaecher; Jennifer Stabenow; Christina Oberle; Jill Schriewer; R Mark Buller; John E Sagartz; Andrew Pekosz
Journal:  Virology       Date:  2008-08-28       Impact factor: 3.616

Review 10.  Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome.

Authors:  Christopher R Braden; Scott F Dowell; Daniel B Jernigan; James M Hughes
Journal:  Emerg Infect Dis       Date:  2013-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.